CoChat
Sign Up
Cited by 151Pancreatic and Hepatic Oncology ResearchCell death mechanisms and regulationSignaling Pathways in Disease

The DOI matches its Crossref record; 44 of the 55 references it cites were found in a registry or an index.

Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression

Open access
Bharadwaj, Uddalak, Marin-Muller, Christian, Li, Min, Chen, Changyi, Yao, Qizhi·2011·Molecular Cancer
DOI 10.1186/1476-4598-10-106PMC PMC3175472
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Previous studies showed that mesothelin (MSLN) plays important roles in survival of pancreatic cancer (PC) cells under anchorage dependent/independent conditions as well as resistance to chemotherapy. The recent success of intratumorally-injected adeno-encoded, chemo/radiation-inducible-promoter driven hTNF-α, (TNFerade) + gemcitabine in pre-clinical models of PC have renewed interest in use of TNF-α as a therapeutic component. To help find additional factors which might affect the therapy, we examined the resistance of MSLN-overexpressing pancreatic cancer cell lines to TNF-α-induced growth inhibition/apoptosis. Methods: Stable MSLN overexpressing MIA PaCa-2 cells (MIA-MSLN), stable MSLN-silenced AsPC-1 cells (AsPC-shMSLN) and other pancreatic cells (MIA-PaCa2, Panc 28, Capan-1, BxPC3, PL 45, Hs 766T, AsPC-1, Capan-2, Panc 48) were used. NF-κB activation was examined by western blots and luciferase reporter assay. TNF-α induced growth inhibition/apoptosis was measured by MTT, TUNEL assay and caspase activation. IL-6 was measured using luminex based assay. Results: Compared to low endogenous MSLN-expressing MIA PaCa-2 and Panc 28 cells, high endogenous MSLN-expressing Capan-1, BxPC3, PL 45, Hs 766T, AsPC-1, Capan-2, Panc 48 cells were resistant to TNF-α induced growth inhibition. Stable MSLN overexpressing MIA-PaCa2 cells (MIA-MSLN) were resistant to TNF-α-induced apoptosis while stable MSLN-silenced AsPC1 cells (AsPC-shMSLN) were sensitive. Interestingly, TNF-α-treated MIA-MSLN cells showed increased cell cycle progression and cyclin A induction, both of which were reversed by caspase inhibition. We further found that MIA-MSLN cells showed increased expression of anti-apoptotic Bcl-XL and Mcl-1; deactivated (p-Ser 75 ) BAD, and activated (p-Ser 70 ) Bcl-2. Constitutively activated NF-κB and Akt were evident in MIA-MSLN cells that could be suppressed by MSLN siRNA with a resultant increase in sensitivity of TNF-α induced apoptosis. Blocking NF-κB using IKK inhibitor wedelolactone also increased sensitivity to TNF-α-mediated cytotoxicity with concomitant decrease in Mcl-1. Blocking Akt using PI3K inhibitor also had a likewise effect presumably affecting cell cycle. MIA-MSLN cells produced increased IL-6 and were increased furthermore by TNF-α treatment. SiRNA-silencing of IL-6 increased TNF-α sensitivity of MIA-MSLN cells. Conclusions: Our study delineates a MSLN-Akt-NF-κB-IL-6-Mcl-1 survival axis that may be operative in PC cells, and might help cancer cells' survival in the highly inflammatory milieu evident in PC. Further, for the success of TNFerade + gemcitabine to be successful, we feel the simultaneous inhibition of components of this axis is also essential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-10-106

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MSLN expression level positively correlates with protection of pancreatic cancer cell lines from TNF-α induced apoptosis. (A). Evaluation of MSLN mRNA expression in PC cell lines. Relative MSLN mRNA levels in pancreatic cancer cell lines MIA PaCa-2, Panc28, Capan-1, BxPC3, PL 45, Hs 766T, AsPC-1, Capan-2 and Panc 48 cells. Total mRNA from the cell lines were reverse transcribed and tested for MSLN expression by Real Time PCR. The results depicted denote MSLN mRNA levels in each cell line normalized to the GAPDH mRNA level. Relative mRNA level is presented as 2^[Ct(GAPDH)-Ct(MSLN)]. The bars denote SD of duplicate data. (B). A panel of PC cells' viability with or without TNF-α treatment. Cells were seeded in 96-well plates, serum-starved for 24 h, and then cultured in serum free medium ± 20/50 ng/ml of TNF-α for 72 h. Viable cells were quantitated by using MTT assay. Relative fold increase in viability is plotted along Y axis. Data plotted show means of triplicate wells.
Figure 1 MSLN expression level positively correlates with protection of pancreatic cancer cell lines from TNF-α induced apoptosis. (A). Evaluation of MSLN mRNA expression in PC cell lines. Relative MSLN mRNA levels in pancreatic cancer cell lines MIA PaCa-2, Panc28, Capan-1, BxPC3, PL 45, Hs 766T, AsPC-1, Capan-2 and Panc 48 cells. Total mRNA from the cell lines were reverse transcribed and tested for MSLN expression by Real Time PCR. The results depicted denote MSLN mRNA levels in each cell line normalized to the GAPDH mRNA level. Relative mRNA level is presented as 2^[Ct(GAPDH)-Ct(MSLN)]. The bars denote SD of duplicate data. (B). A panel of PC cells' viability with or without TNF-α treatment. Cells were seeded in 96-well plates, serum-starved for 24 h, and then cultured in serum free medium ± 20/50 ng/ml of TNF-α for 72 h. Viable cells were quantitated by using MTT assay. Relative fold increase in viability is plotted along Y axis. Data plotted show means of triplicate wells.CC BY · PubMed Central
Figure 2 MSLN overexpression protects PC cells from TNF-α induced cell viability decrease and apoptosis. (A). MIA-MSLN and control cells viability assay with or without TNF-α treatment. About 3000 cells were plated in 96 well plates, serum starved for 24 h and treated with TNF-α at 20 ng/ml for 96 h after which viability was measured by MTT. Relative increase in viability was measured by dividing viability at a time point by viability of same cells at day 0 (day after plating) and is plotted along Y axis. Data plotted show mean of triplicate wells. Bars denote s.d. of triplicate data. *, # denote p < 0.05, **, ## denote p < 0.01, compared with controls by using student t test. (B). MIA-MSLN cells are resistant to TNF-α induced apoptosis using TUNEL assay. Cells were treated ± 20 ng/ml of TNF-α for 72 h and apoptosis was measured by TUNEL assay. Representative flow histograms show percentage of dUTP-FITC-positive apoptotic cells. Lower panel shows mean number of TUNEL positive cells (duplicate wells). (C). siRNA-silencing MSLN renders MIA-MSLN cells become TNF-α-sensitive measured by TUNEL assay. MIA-V/MIA-MSLN ells were plated in 6 well plates, transfected with siRNA, 24 h after transfection media was replaced by growth media, cells were serum starved and treated with TNF-α at 20 ng/ml for 72 h after which cells were collected, fixed and tested for DNA strand breaks by TUNEL assay. Bars denote s.d. of duplicate data. *, # denote p < 0.05, **, ## denote p < 0.01, compared with controls by using student t test.
Figure 2 MSLN overexpression protects PC cells from TNF-α induced cell viability decrease and apoptosis. (A). MIA-MSLN and control cells viability assay with or without TNF-α treatment. About 3000 cells were plated in 96 well plates, serum starved for 24 h and treated with TNF-α at 20 ng/ml for 96 h after which viability was measured by MTT. Relative increase in viability was measured by dividing viability at a time point by viability of same cells at day 0 (day after plating) and is plotted along Y axis. Data plotted show mean of triplicate wells. Bars denote s.d. of triplicate data. *, # denote p < 0.05, **, ## denote p < 0.01, compared with controls by using student t test. (B). MIA-MSLN cells are resistant to TNF-α induced apoptosis using TUNEL assay. Cells were treated ± 20 ng/ml of TNF-α for 72 h and apoptosis was measured by TUNEL assay. Representative flow histograms show percentage of dUTP-FITC-positive apoptotic cells. Lower panel shows mean number of TUNEL positive cells (duplicate wells). (C). siRNA-silencing MSLN renders MIA-MSLN cells become TNF-α-sensitive measured by TUNEL assay. MIA-V/MIA-MSLN ells were plated in 6 well plates, transfected with siRNA, 24 h after transfection media was replaced by growth media, cells were serum starved and treated with TNF-α at 20 ng/ml for 72 h after which cells were collected, fixed and tested for DNA strand breaks by TUNEL assay. Bars denote s.d. of duplicate data. *, # denote p < 0.05, **, ## denote p < 0.01, compared with controls by using student t test.CC BY · PubMed Central
Figure 3 MSLN overexpression makes PC cells resistant to TNF-α induced apoptosis through reduced Caspase 3 cleavage and up regulated anti-apoptotic proteins. (A). Reduced Caspase 3 cleavage in MIA-MSLN cells by 20 ng/ml of TNF-α treatment for 72 h. (B). Silencing endogenous MSLN in AsPC-3 cells renders it sensitive to TNF-α induced apoptosis through increased Caspase 3 cleavage. Panel (i) shows the reduction of MSLN expression level in AsPC-shMSLN stable cell line. Panel (ii) shows the increased caspase 3 cleavage upon TNF-α treatment. (C). Pre-treatment with pan-caspase inhibitor zVAD-fmk renders MIA-V cells resistant to TNF-α-induced apoptosis. Cells were treated with 20 ng/ml of TNF-α for 72 h and then stained with TUNEL assay. (D). Pro and anti-apoptotic molecules expression in MIA-V/MIA-MSLN cells with or without treatment of 20 ng/ml TNF-α assayed by Western blot. (E). Effect of different TNF-α doses on selected pro/anti-apoptotic molecules expression in MIA-V/MIA-MSLN cells. (F). Effect of zVAD-fmk pre-treatment on various pro and anti-apoptotic molecules expression in MIA-V/MIA-MSLN cells after treatment with 50 ng/ml of TNF-α for 72 h.
Figure 3 MSLN overexpression makes PC cells resistant to TNF-α induced apoptosis through reduced Caspase 3 cleavage and up regulated anti-apoptotic proteins. (A). Reduced Caspase 3 cleavage in MIA-MSLN cells by 20 ng/ml of TNF-α treatment for 72 h. (B). Silencing endogenous MSLN in AsPC-3 cells renders it sensitive to TNF-α induced apoptosis through increased Caspase 3 cleavage. Panel (i) shows the reduction of MSLN expression level in AsPC-shMSLN stable cell line. Panel (ii) shows the increased caspase 3 cleavage upon TNF-α treatment. (C). Pre-treatment with pan-caspase inhibitor zVAD-fmk renders MIA-V cells resistant to TNF-α-induced apoptosis. Cells were treated with 20 ng/ml of TNF-α for 72 h and then stained with TUNEL assay. (D). Pro and anti-apoptotic molecules expression in MIA-V/MIA-MSLN cells with or without treatment of 20 ng/ml TNF-α assayed by Western blot. (E). Effect of different TNF-α doses on selected pro/anti-apoptotic molecules expression in MIA-V/MIA-MSLN cells. (F). Effect of zVAD-fmk pre-treatment on various pro and anti-apoptotic molecules expression in MIA-V/MIA-MSLN cells after treatment with 50 ng/ml of TNF-α for 72 h.CC BY · PubMed Central
Figure 4 TNF-α induces S phase progression and induction of cyclin A in MIA-MSLN cells. (A). Cell cycle analysis of MIA-V/MIA-MSLN cells treated with 10/20 ng/ml of TNF-α for 24 h. (B). Cell cycle related molecules detection by western blot using the lysates from cells treated as in (A). (C). Cell cycle analysis of MIA-V/MIA-MSLN cells after pre-treatment with zVAD-fmk and then treated with 50 ng/ml of TNF-α for 72 h. (D). Cyclin A detection by western blot using the cell lysates from cells treated as in (C).
Figure 4 TNF-α induces S phase progression and induction of cyclin A in MIA-MSLN cells. (A). Cell cycle analysis of MIA-V/MIA-MSLN cells treated with 10/20 ng/ml of TNF-α for 24 h. (B). Cell cycle related molecules detection by western blot using the lysates from cells treated as in (A). (C). Cell cycle analysis of MIA-V/MIA-MSLN cells after pre-treatment with zVAD-fmk and then treated with 50 ng/ml of TNF-α for 72 h. (D). Cyclin A detection by western blot using the cell lysates from cells treated as in (C).CC BY · PubMed Central
Figure 5 MSLN overexpression is associated with activation of NF-κB and Akt activity in PC cells. (A). Enhanced NF-κB reporter gene activity in MIA-MSLN cells. Data plotted was measured as ratio of co-transfected firefly-NF-κB reporter normalized to Actin-Renilla. ** denote p < 0.01, compared with controls, t test. (B). Nuclear protein from MIA-MSLN and control cells were subjected to western blot to detect nuclear-translocated p65, p50 and nuclear envelop protein Lamin A (panel i). Panel ii showed inhibited nuclear protein translocation when MIA-MSLN cells were transfected with MSLN specific shRNA encoding plasmid or control plasmids. (C). Whole cell extract (WCE) or nuclear protein from MIA-V and two pools of MIA-MSLN cells were probed for various IκB-α degradation pathway proteins in western blot. (D). Whole protein from MIA-V/MIA-MSLN (panel i) and from the AsPC-1 shMSLN and control cells (panel ii) were probed for various PI3k-Akt pathway proteins. Note: (panel i) data has individual lanes combined from a single electrophoresis gel.
Figure 5 MSLN overexpression is associated with activation of NF-κB and Akt activity in PC cells. (A). Enhanced NF-κB reporter gene activity in MIA-MSLN cells. Data plotted was measured as ratio of co-transfected firefly-NF-κB reporter normalized to Actin-Renilla. ** denote p < 0.01, compared with controls, t test. (B). Nuclear protein from MIA-MSLN and control cells were subjected to western blot to detect nuclear-translocated p65, p50 and nuclear envelop protein Lamin A (panel i). Panel ii showed inhibited nuclear protein translocation when MIA-MSLN cells were transfected with MSLN specific shRNA encoding plasmid or control plasmids. (C). Whole cell extract (WCE) or nuclear protein from MIA-V and two pools of MIA-MSLN cells were probed for various IκB-α degradation pathway proteins in western blot. (D). Whole protein from MIA-V/MIA-MSLN (panel i) and from the AsPC-1 shMSLN and control cells (panel ii) were probed for various PI3k-Akt pathway proteins. Note: (panel i) data has individual lanes combined from a single electrophoresis gel.CC BY · PubMed Central
Figure 6 Inhibiting NF-κB/Akt pathway or endogenous IL-6 abrogates MIA-MSLN cells resistance to TNF-α-induced apoptosis. (A). MIA-MSLN cell viability was reduced upon pre-treatment with IKK inhibitor wedelolactone and then 20 ng/ml of TNF-α for 72 h. (B). MIA-MSLN cell viability was reduced upon pre-treatment with PI3K inhibitor Ly 2940002 and then 20 ng/ml of TNF-α for 72 h. (C). Cell apoptosis was determined by TUNEL assay in samples treated as in (A) and (B). (D). Proteins from similarly treated cells were subjected to western blot to detect caspase 3 cleavage and key pro/anti-apoptotic molecules.
Figure 6 Inhibiting NF-κB/Akt pathway or endogenous IL-6 abrogates MIA-MSLN cells resistance to TNF-α-induced apoptosis. (A). MIA-MSLN cell viability was reduced upon pre-treatment with IKK inhibitor wedelolactone and then 20 ng/ml of TNF-α for 72 h. (B). MIA-MSLN cell viability was reduced upon pre-treatment with PI3K inhibitor Ly 2940002 and then 20 ng/ml of TNF-α for 72 h. (C). Cell apoptosis was determined by TUNEL assay in samples treated as in (A) and (B). (D). Proteins from similarly treated cells were subjected to western blot to detect caspase 3 cleavage and key pro/anti-apoptotic molecules.CC BY · PubMed Central
Figure 7 High levels of IL-6 in MIA-MSLN cells plays important role in resistance to TNF-α-mediated cytotoxicity. (A). Elevated constitutive and TNF-α induced IL-6 expression in MIA-MSLN cells using Luminex-based IL-6 assay kit. Y-axis represents fluorescence corresponding to IL-6-levels. Bars denote SD of duplicate data. (B). Inhibiting endogenous IL-6 by siRNA sensitizes MIA-MSLN cells to TNF-α-induced apoptosis. MIA-MSLN cells were either mock-transfected (control) or transfected with non-targeting (siNT) or IL-6 specific siRNA pools (siIL-6) and treated with 20 ng/ml of TNF-α for 72 h and analyzed for TUNEL positivity. Flow histograms show percentage of dUTP-FITC-positive apoptotic cells. Plots are representatives of three independent experiments.
Figure 7 High levels of IL-6 in MIA-MSLN cells plays important role in resistance to TNF-α-mediated cytotoxicity. (A). Elevated constitutive and TNF-α induced IL-6 expression in MIA-MSLN cells using Luminex-based IL-6 assay kit. Y-axis represents fluorescence corresponding to IL-6-levels. Bars denote SD of duplicate data. (B). Inhibiting endogenous IL-6 by siRNA sensitizes MIA-MSLN cells to TNF-α-induced apoptosis. MIA-MSLN cells were either mock-transfected (control) or transfected with non-targeting (siNT) or IL-6 specific siRNA pools (siIL-6) and treated with 20 ng/ml of TNF-α for 72 h and analyzed for TUNEL positivity. Flow histograms show percentage of dUTP-FITC-positive apoptotic cells. Plots are representatives of three independent experiments.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 6

  1. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q: Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008, 7: 286-296. 10.1158/1535-7163.MCT-07-0483 · DOI
  2. Fernandez A, Marin MC, McDonnell T, Ananthaswamy HN: Differential sensitivity of normal and Ha-ras-transformed C3H mouse embryo fibroblasts to tumor necrosis factor: induction of bcl-2, c-myc, and manganese superoxide dismutase in resistant cells. Oncogene. 1994, 9: 2009-2017.
  3. Komori A, Yatsunami J, Suganuma M, Okabe S, Abe S, Sakai A, Sasaki K, Fujiki H: Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res. 1993, 53: 1982-1985.
  4. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM: Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res. 2003, 63: 8330-8337.
  5. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001, 7: 3862-3868.
  6. Kalthoff H, Roeder C, Humburg I, Thiele HG, Greten H, Schmiegel W: Modulation of platelet-derived growth factor A- and B-chain/c-sis mRNA by tumor necrosis factor and other agents in adenocarcinoma cells. Oncogene. 1991, 6: 1015-1021.

Cited by

Sorted by citations

Metadata

Authors
Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q.
Affiliations
Baylor College of Medicine (US)
Corresponding author
Yao, Qizhi
ORCID
Venue
Molecular Cancer
Publisher
Springer Science and Business Media LLC
Published
2011-08-31
Volume
10
Issue
1
Pages
106-106
ISSN
1476-4598 (ISSN-L)
DOI
10.1186/1476-4598-10-106
PMC
PMC3175472
OpenAlex
W2102073127
Cited by
151
References
55
Citations by year
2026: 9 · 2025: 19 · 2024: 13 · 2023: 7 · 2022: 10 · 2021: 13 · 2020: 17 · 2019: 14 · 2018: 6 · 2017: 10 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 6 · 2012: 10
FWCI
3.31
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (CA140828, R21CA140828)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
mesothelin, pancreatic cancer, TNF-α, apoptosis resistance, interleukin-6, Mcl-1, Bcl-xL, Bad phosphorylation, cell cycle progression, cyclin A, caspase activation, gemcitabine, chemosensitization, tumor microenvironment
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Mesothelin, Antineoplastic Agents, Cell Survival, Chromones, Coumarins, Enzyme Activation, Humans, Morpholines, Pancreatic Neoplasms, Recombinant Proteins, Tumor Necrosis Factor-alpha, Interleukin-6, Gene Expression, S Phase, NF-kappa B, Apoptosis, Genes, Reporter, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Phosphatidylinositol 3-Kinases, Cyclin A, Protein Transport, RNA Interference, Cell Line, Tumor, Luciferases, Renilla, Apoptosis Regulatory Proteins, Proto-Oncogene Proteins c-akt, I-kappa B Kinase, Caspase 3, Gene Knockdown Techniques, GPI-Linked Proteins, Myeloid Cell Leukemia Sequence 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review